Hannah M Hicks

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Induced Apoptosis

Metastatic Colorectal Cancer

Cell Proliferation

Top Venues

Cancer biology & therapy

Molecular cancer research : MCR

Molecular carcinogenesis

This page only lists publications with an associated author ORCID identifier.

Publications

Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Veronica L Nassar, Jane Lund, Madison M Rose, Rebecca E Schweppe
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy 25 (1) (2024)
Hannah M Hicks, Nikita Pozdeyev, Sharon B Sams, Umarani Pugazhenthi, Elise S Bales, Marie Claude Hofmann, Logan R McKenna, Rebecca E Schweppe
Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2. Molecular cancer research : MCR (2023)
Hannah M Hicks, Logan R McKenna, Veronica L Espinoza, Nikita Pozdeyev, Laura A Pike, Sharon B Sams, Daniel LaBarbera, Philip Reigan, Christopher D Raeburn, Rebecca E Schweppe
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Molecular carcinogenesis 60 (3) (2021)